Nintedanib-13C, d3

Nintedanib-13C, d3 is the 13C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

Product Specifications

Product Name Alternative

BIBF 1120-13C, d3

UNSPSC

12352005

Target

FGFR; Isotope-Labeled Compounds; PDGFR; VEGFR

Type

Isotope-Labeled Compounds

Related Pathways

Others; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

99.0

Solubility

10 mM in DMSO|DMSO : 11.36mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(N(C)C(CN4CCN([13C]([2H])([2H])[2H])CC4)=O)C=C3)/C5=CC=CC=C5)OC

Molecular Formula

C30 13CH30D3N5O4

Molecular Weight

543.64

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.|[2]Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res, 2008, 68 (12), 4774-4782.|[3]Roth GJ, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) . J Med Chem, 2009, 52 (14), 4466-4480.